Exelixis, Inc. (EXEL) Stock: Price, Forecast & Analyst Target
Exelixis, Inc. (EXEL) — MoonshotScore 98/100 (Exceptional band), calculated Oct 6, 2026. Price $58.85 (+0.79%), as of the Oct 5, 2026 trading session; market cap $14.8B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 17.63× (market value Oct 5, 2026; cash Jul 3, 2026) · expected results Nov 3, 2026
Exelixis, Inc. · EXEL · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Exelixis is an oncology drug developer with an established commercial franchise, not a biotechnology company waiting for its pipeline to produce meaningful revenue. The case rests on whether CABOMETYX can keep expanding product economics while research spending builds therapies capable of reducing dependence on cabozantinib.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Exelixis (EXEL)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $629M (Q2 FY2026, quarter ended Jul 2026)
- EPS beat 8 of 8
- Altman Z 16.14 · Piotroski F 7
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional |
The score was 98 in the stored Oct 5, 2026 snapshot and remains 98 in the current publication computed Oct 6, 2026 (0). This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $58.85 | |
| Change on the day | +0.79% | |
| 52-week range | $33.76 – $61.14 | |
| Market capitalisation | $14.8B | |
| Price / earnings (trailing) | 17.89 | |
| Shares traded on the day | 2.6M | |
| Beta (volatility vs the S&P 500) | 0.42 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for Exelixis (EXEL): Strongly Bullish
87/100 · A+Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 6, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 22, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 22, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the EXEL film — every key number, told as a short cinematic story
~2 min · open the film
What is Exelixis (EXEL), and what does it report?
Short answer · as of
Exelixis discovers, develops and markets cancer medicines, led by CABOMETYX and COMETRIQ, which share cabozantinib as their active compound.
Research dated 2026-09-13.
Exelixis discovers, develops and markets cancer medicines, led by CABOMETYX and COMETRIQ, which share cabozantinib as their active compound. Its portfolio also includes partnered products, while its development work spans kinase inhibitors and an antibody-drug conjugate for solid tumors and other cancers.
Reported revenue is not a pure royalty stream. Product sales supply the dominant contribution, supplemented by license and collaboration revenue, so changes in prescribing demand matter directly alongside milestones and partner economics.
What do the latest results show for Exelixis (EXEL)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $629M.
Research dated 2026-09-13.
Revenue and gross profit continued to rise in the latest period, while operating profit eased despite the higher top line. Research and commercial spending increased, showing that incremental revenue did not flow through untouched, although net income remained strong and diluted earnings stayed well above earlier periods.
Recent earnings have generally exceeded expectations even when revenue has occasionally fallen short. That pattern points to expense control and high product gross margins as important contributors to earnings delivery, rather than revenue surprises alone.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $628.69M Jul 3, 2026
- Latest quarter · R&D
- $211.99M Jul 3, 2026
- Latest quarter · SG&A
- $147.63M Jul 3, 2026
- Latest quarter · FMP standardized operating result
- $248.41M Jul 3, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 3, 2026 | $628.69M | $211.99M | $147.63M | $248.41M |
| Apr 3, 2026 | $610.81M | $199.92M | $139.60M | $251.34M |
| Jan 2, 2026 | $598.66M | $213.25M | $123.02M | $235.22M |
| Oct 3, 2025 | $597.75M | $199.16M | $123.66M | $236.54M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $628.69M Aug 5, 2026
- Latest report · revenue estimate
- $636.40M Aug 5, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 5, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 5, 2026 | $628.69M | $636.40M | $0.9100 | $0.8530 |
| May 5, 2026 | $610.81M | $607.51M | $0.8700 | $0.7650 |
| Feb 10, 2026 | $598.66M | $596.52M | $0.9400 | $0.7700 |
| Nov 4, 2025 | $597.75M | $590.16M | $0.7800 | $0.6850 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $629M | $212M | $0.82 (diluted) |
| Q1 FY2026 | $611M | $210M | $0.79 (diluted) |
| Q4 FY2025 | $599M | $245M | $0.88 (diluted) |
| Q3 FY2025 | $598M | $194M | $0.70 (diluted) |
What are the financial strengths and risks for Exelixis (EXEL)?
Short answer
Cash and short-term investments were $839.39M at the Jul 3, 2026 balance-sheet date. Operating cash flow was $307.74M for the quarter ended Jul 3, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Exelixis combines sustained profitability with substantial operating cash generation and modest capital expenditure. Cash and investments comfortably exceed debt and total liabilities, giving the company room to fund development without relying on near-term external financing.
The balance sheet is stronger than the movement in cash and short-term investments alone suggests because a meaningful portion of liquidity sits in longer-term investments. Even so, the shorter-duration balance has declined across the reported window, so continued cash generation matters as research and commercial spending remain substantial.
The business risk is concentration: product revenue dominates, and the commercial portfolio is anchored by medicines derived from cabozantinib. A deterioration in that franchise could pressure revenue, profit and internally funded pipeline investment at the same time.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $307.74M Jul 3, 2026
- Previous quarter · operating cash flow
- $251.85M Apr 3, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jul 3, 2026 | $307.74M | −$9.32M |
| Apr 3, 2026 | $251.85M | −$2.03M |
| Jan 2, 2026 | $333.52M | −$7.16M |
| Oct 3, 2025 | $290.32M | −$6.73M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Exelixis (EXEL)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026. The number it tests is the $3.51 EPS analysts carry for it.
Research dated 2026-09-13.
Watch whether CABOMETYX-led product revenue keeps rising while operating profit resumes growth. The latest period paired a stronger top line with higher research and selling costs, making expense absorption as informative as headline revenue.
Operating cash flow should remain aligned with reported profit, and the mix between short-term cash and longer-term investments deserves attention when judging financial flexibility. Pipeline progress matters most where it can broaden the franchise beyond cabozantinib rather than merely add spending.
The scheduled earnings release carries expectations for further revenue and earnings growth. The useful comparison will be against the recent pattern of steady revenue expansion, resilient margins and earnings delivery that has often surpassed forecasts.
How does Exelixis compare with its peers?
Short answer
Exelixis's score ranks tied for 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Exelixis differs from development-stage biotechnology companies because marketed oncology products already support profit, cash generation and ongoing research. It also differs from broadly diversified pharmaceutical groups: commercial exposure is concentrated around cabozantinib, while license and collaboration arrangements extend the portfolio and geographic reach.
That combination creates an unusual financial shape for biotechnology: very high gross margins, strong returns and low leverage alongside material research spending. The tradeoff is that current economics depend heavily on an established franchise while the pipeline carries the burden of diversification.
| Company | Price | Market value | Score |
|---|---|---|---|
| Exelixis (EXEL) — this page | $58.85 | $14.8B | 98 |
| $334.85 Oct 5, 2026 | $9.87B | 98 5-pillar Oct 6, 2026 | |
| $114.13 Oct 5, 2026 | $23.1B | 98 5-pillar Oct 6, 2026 | |
| $108.31 Oct 5, 2026 | $12.9B | 97 5-pillar Oct 6, 2026 | |
| $536.40 Oct 5, 2026 | $22.8B | 97 5-pillar Oct 6, 2026 | |
| $144.21 Oct 5, 2026 | $14.5B | 93 5-pillar Oct 6, 2026 | |
| $72.58 Oct 5, 2026 | $11.4B | 93 5-pillar Oct 6, 2026 | |
| $122.03 Oct 5, 2026 | $13.1B | 91 5-pillar Oct 6, 2026 | |
| $228.03 Oct 5, 2026 | $14.2B | 88 5-pillar Oct 6, 2026 | |
| $140.65 Oct 5, 2026 | $9.98B | 83 5-pillar Oct 6, 2026 | |
| $140.63 Oct 5, 2026 | $9.08B | 76 5-pillar Oct 6, 2026 | |
| $57.54 Oct 5, 2026 | $11.1B | 65 5-pillar Oct 6, 2026 | |
| $207.68 Oct 5, 2026 | $44.2B | 57 5-pillar Oct 6, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $46.00 – $56.00
- Consensus target
- $51.78
- Median target
- $52.00
- Revenue estimate
- $2.55B
- EPS estimate
- $3.51
Consensus record · Captured .
Measured against a quoted price of $58.85 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 10, 2026
- Transactions
- 32
- Identified insiders
- 15
- Purchases
- 0
- Sales
- 10
- Other transactions
- 22
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 779 Period end Jun 30, 2026
- Previous quarter · holders
- 722 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 29,075,377 |
| Farallon Capital Management LLC | 13,468,010 |
| Renaissance Technologies LLC | 13,427,993 |
| Vanguard Portfolio Management LLC | 12,043,122 |
| Aqr Capital Management LLC | 11,023,943 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Exelixis (EXEL)?
EXEL Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is CABOMETYX so important to Exelixis?
CABOMETYX is a marketed cabozantinib therapy and sits at the center of a product-led revenue base. Its commercial durability helps determine how much profit and cash Exelixis can direct toward pipeline development.
How are CABOMETYX and COMETRIQ related?
CABOMETYX and COMETRIQ are distinct marketed formulations derived from cabozantinib, a compound that inhibits several kinases involved in tumor biology. Their shared origin makes cabozantinib central to the current commercial portfolio.
Do license and collaboration payments drive Exelixis revenue?
Product sales are the dominant reported revenue source, while license and collaboration revenue provide additional contributions. Exelixis therefore has direct commercial exposure rather than relying mainly on partner payments.
Can Exelixis fund its oncology pipeline internally?
Strong operating cash flow, minimal capital needs and liquidity well above debt support internal research funding. Continued CABOMETYX-led cash generation remains important because research spending is substantial and the shorter-duration cash balance has declined across the reported window.
What is the EXEL stock price today?
The last price recorded on this page for Exelixis, Inc. (EXEL) is $58.85, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the EXEL price target?
The analyst consensus price target for Exelixis, Inc. (EXEL) is $51.78 (range $46.00 to $56.00, median $52.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (83 figures)
The 83 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Alameda, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "1851 Harbor Bay Parkway, Alameda, CA, 94502, US". |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $58.85 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T20:00:02.000Z. | |
px.change | Change on the day | +0.79% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $14.8B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:02.000Z. Captured from FMP at 2026-10-06T08:37:16.139Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.46 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $629M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 17.89 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.6M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.42 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Michael Morrissey | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.founder | Founder named in the filing | Stelios Papadopoulos — Co-Founder & Independent Chair of the Board | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 1,077 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2026: FY2021 revenue $1.43B, net result $231.06M; FY2022 revenue $1.61B, net result $182.28M; FY2023 revenue $1.83B, net result $207.77M; FY2025 revenue $2.17B, net result $521.27M; FY2026 revenue $2.32B, net result $782.57M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | License $214.38M · Product $2.12B · Collaboration $197.32M · Product, Gross $3.01B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 96.5% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-07-03.revenue_k | Revenue — period end 2026-07-03 | $628.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-03.rd_k | R&D — period end 2026-07-03 | $211.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-03.sga_k | SG&A — period end 2026-07-03 | $147.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-03.operating_result_k | FMP standardized operating result — period end 2026-07-03 | $248.41M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-03.revenue_k | Revenue — period end 2026-04-03 | $610.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-03.rd_k | R&D — period end 2026-04-03 | $199.92M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-03.sga_k | SG&A — period end 2026-04-03 | $139.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-03.operating_result_k | FMP standardized operating result — period end 2026-04-03 | $251.34M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-02.revenue_k | Revenue — period end 2026-01-02 | $598.66M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-02.rd_k | R&D — period end 2026-01-02 | $213.25M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-02.sga_k | SG&A — period end 2026-01-02 | $123.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-02.operating_result_k | FMP standardized operating result — period end 2026-01-02 | $235.22M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-03.revenue_k | Revenue — period end 2025-10-03 | $597.75M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-03.rd_k | R&D — period end 2025-10-03 | $199.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-03.sga_k | SG&A — period end 2025-10-03 | $123.66M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-03.operating_result_k | FMP standardized operating result — period end 2025-10-03 | $236.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-05.revenue_actual | Revenue · reported — report date 2026-08-05 | $628.69M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.revenue_estimated | Revenue · estimate — report date 2026-08-05 | $636.40M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_actual | EPS · reported — report date 2026-08-05 | $0.9100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_estimated | EPS · estimate — report date 2026-08-05 | $0.8530 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_actual | Revenue · reported — report date 2026-05-05 | $610.81M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_estimated | Revenue · estimate — report date 2026-05-05 | $607.51M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | $0.8700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | $0.7650 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.revenue_actual | Revenue · reported — report date 2026-02-10 | $598.66M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.revenue_estimated | Revenue · estimate — report date 2026-02-10 | $596.52M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.eps_actual | EPS · reported — report date 2026-02-10 | $0.9400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.eps_estimated | EPS · estimate — report date 2026-02-10 | $0.7700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $597.75M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $590.16M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | $0.7800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | $0.6850 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $839.39M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $307.74M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-07-03. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $544.93M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $165.93M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 7.88× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-07-03.operating_cash_flow_m | Operating cash flow — period end 2026-07-03 | $307.74M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-03.operating_cash_flow_m | Operating cash flow — period end 2026-04-03 | $251.85M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-07-03.capex_m | Capital expenditure (reported) — period end 2026-07-03 | −$9.32M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-03.capex_m | Capital expenditure (reported) — period end 2026-04-03 | −$2.03M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-01-02.operating_cash_flow_m | Operating cash flow — period end 2026-01-02 | $333.52M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-01-02.capex_m | Capital expenditure (reported) — period end 2026-01-02 | −$7.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-10-03.operating_cash_flow_m | Operating cash flow — period end 2025-10-03 | $290.32M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-10-03.capex_m | Capital expenditure (reported) — period end 2025-10-03 | −$6.73M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $46.00 – $56.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $51.78 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $52.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 32 transactions · 0 purchases, 10 sales, 22 other transactions · 15 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Aug 10, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 779 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 722 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 29,075,377 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Farallon Capital Management LLC — shares in provider snapshot | 13,468,010 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Renaissance Technologies LLC — shares in provider snapshot | 13,427,993 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 12,043,122 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Aqr Capital Management LLC — shares in provider snapshot | 11,023,943 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 16.14 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
px.range52 | 52-week range | $33.76 – $61.14 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
earn.est_eps | EPS estimate, FY2027 | $3.51 | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2027 | $2.55B | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 17.63× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $839.39M at Jul 3, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-07-03. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-05.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($628.69M) with the recorded estimate ($636.40M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-05.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.9100) with the recorded estimate ($0.8530) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 98 of 100 · Exceptional · pillars 98 / 94 / 62 / 95 / 84 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 98 (stored snapshot Oct 5, 2026) → 98 (current publication computed Oct 6, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-07-03. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-07-03.revenue_k,fin.q_table.depth.2026-07-03.rd_k,fin.q_table.depth.2026-07-03.sga_k,fin.q_table.depth.2026-07-03.operating_result_k,fin.q_table.depth.2026-04-03.revenue_k,fin.q_table.depth.2026-04-03.rd_k,fin.q_table.depth.2026-04-03.sga_k,fin.q_table.depth.2026-04-03.operating_result_k,fin.q_table.depth.2026-01-02.revenue_k,fin.q_table.depth.2026-01-02.rd_k,fin.q_table.depth.2026-01-02.sga_k,fin.q_table.depth.2026-01-02.operating_result_k,fin.q_table.depth.2025-10-03.revenue_k,fin.q_table.depth.2025-10-03.rd_k,fin.q_table.depth.2025-10-03.sga_k,fin.q_table.depth.2025-10-03.operating_result_k. - Earnings-history note. Source series as of 2026-08-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-05.revenue_actual,earn.history.depth.2026-08-05.revenue_estimated,earn.history.depth.2026-08-05.revenue_actual.comparison,earn.history.depth.2026-08-05.eps_actual.comparison,earn.history.depth.2026-08-05.eps_actual,earn.history.depth.2026-08-05.eps_estimated,earn.history.depth.2026-05-05.revenue_actual,earn.history.depth.2026-05-05.revenue_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-02-10.revenue_actual,earn.history.depth.2026-02-10.revenue_estimated,earn.history.depth.2026-02-10.eps_actual,earn.history.depth.2026-02-10.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated. - Cash-flow note. Source series as of 2026-07-03. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-07-03.operating_cash_flow_m,fin.opcf.depth.2026-04-03.operating_cash_flow_m,fin.opcf.depth.2026-07-03.capex_m,fin.opcf.depth.2026-04-03.capex_m,fin.opcf.depth.2026-01-02.operating_cash_flow_m,fin.opcf.depth.2026-01-02.capex_m,fin.opcf.depth.2025-10-03.operating_cash_flow_m,fin.opcf.depth.2025-10-03.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | License: $214.38M; Product: $2.12B; Collaboration: $197.32M; Product, Gross: $3.01B | 2026-01-02 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-07-03 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2026-01-02 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Trailing twelve-month ratio set | Quick ratio: 3.38; Current ratio: 3.46; Debt to equity: 0.09; Net margin: 35.3%; Gross margin: 96.5%; Operating margin: 39.9%; Return on assets: 34.5%; Return on equity: 42.5% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-05 | FMP | Financial Modeling Prep (FMP) earnings |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-07-03 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $165.93M; Liquidity basis: cash and short-term investments; Total liabilities: $650.47M; Cash and short-term investments: $839.39M; Cash and investments: $1.38B; Long-term investments: $544.93M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-07-03 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.38B; Cash and short-term investments: $839.40M; Long-term investments: $544.90M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-07-03 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-07-03 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-07-03; From: 2024-09-27; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $839.40M; Decline: $349.80M; Opening balance: $1.19B; Average change per period: $50.00M Change in cash, cash equivalents and short-term investments between the 2024-09-27 and 2026-07-03 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-07-03 | COMPUTED | Computed from reported balances |
| Next earnings report | Date: 2026-11-03; EPS estimate: $0.89 per share; Revenue estimate: $649.57M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.
ETFs that hold EXEL
Funds in our ETF coverage that list EXEL among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ERShares Private-Public Crossover ETF (XOVR) | 3.23% |